Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model | Zendy

George G. Zhanel | Zendy; E. Rossnagel | Zendy; Kimberly A. Nichol | Zendy; Leonie Cox | Zendy; James A. Karlowsky | Zendy; Sheryl Zelenitsky | Zendy; Ayman Noreddin | Zendy; D. J. Hoban | Zendy

Open Access

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model

Author(s) -

George G. Zhanel,

E. Rossnagel,

Kimberly A. Nichol,

Leonie Cox,

James A. Karlowsky,

Sheryl Zelenitsky,

Ayman Noreddin,

D. J. Hoban

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr110

Subject(s) - staphylococcus aureus , vancomycin , methicillin resistant staphylococcus aureus , microbiology and biotechnology , medicine , pharmacodynamics , cephalosporin , antibiotics , cmax , pharmacokinetics , pharmacology , bacteria , biology , genetics

This study assessed the pharmacodynamics of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA), heteroresistant (h) vancomycin-intermediate S. aureus (hVISA), VISA and vancomycin-resistant S. aureus (VRSA) using an in vitro model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research